Live feed05:36:00·1960dPRReleasevia QuantisnowKazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SEByQuantisnow·Wall Street's wire, on your screen.SNY· SanofiKZIA· Kazia Therapeutics LimitedHealth Care
